STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Frank Pallone, the ranking member of the House Committee on Energy and Commerce, asked GAO in an Oct. 27 letter to review whether TrumpRx has saved Americans any money.
- White House said TrumpRx, which launched in February, has helped Americans save $700 million.
- TrumpRx does not sell or dispense drugs; it directs consumers to coupons or links for discounts.
- Trump administration failed to disclose key information needed to evaluate whether TrumpRx provided any meaningful financial benefit, Pallone wrote.
- White House reached most-favored nation agreements with more than two dozen drugmakers, but key details about those agreements were not disclosed.
Why it matters: The administration’s $700 million savings claim gives TrumpRx a concrete measure of consumer benefit, but the platform only links users to discounts and the terms of agreements with more than two dozen drugmakers remain undisclosed. A GAO review would test that headline figure against information the administration has not publicly provided.
Ask SkimNews
